Coherus Oncology, Inc.

Good day and thank you for standing by. Welcome to the Q2 2026 Cohorus Oncology, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1, 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1, 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Carrie Graham. Please go ahead.

Thank you, Heidi. Good afternoon and welcome to Go Harris Oncology's second quarter 2026 earnings conference call. Joining me today to discuss our results are Denny Lanfear, Chief Executive Officer, Go Harris, Dr. Rosh Dias, Chief Medical Officer, Dr. Theresa Lavallee, Chief Scientific and Development Officer, Sameer Goregaoker, Chief Commercial Officer, and Bryan McMichael, Chief Financial Officer. Before we get started, I would like to remind you that today's call includes forward-looking statements regarding O'Hara's current expectations about future events. Actual results may vary significantly, and we undertake no duty to update or revise any forward-looking statements. Please see the press release that we issued today and our quarterly report on Form 10-Q for more information on risks and uncertainties. And now we'll turn the call over to Denny.

Thank you, Carrie, and thank you all for joining us this afternoon on our Q2 2026 quarterly call. As you know, we are now in an exciting period of initial clinical data generation and readouts, not definitive data reporting, and we'd like to provide you with the available insights on how things look so far. But first, let me make a few remarks about the scientific focus on overcoming immune resistance in cancer to provide you with a lens to reach to view our pipeline and our development strategy. A review of the data on immuno-oncology drugs in cancer reminds us that immunotherapy's benefit is primarily seen at the far end of the survival curve, where it matters most to both patients and regulators. Additionally, the combination agents can make a substantial difference. A good example is the combination of chemotherapy and PD-1s, where PD-1s revolutionized cancer care by addressing immune invasion and showed some of the most pronounced survival benefits when used in combination with drugs that lead to tumor cell death. It's essential to keep in mind that Tegmo-Ketog as a Treg depleting agent is mechanistically positioned, not as another response rate agent like chemo or ADCs. but as a horizontally enabling durability layer that removes the break, Tregs, which potentially limit both depth and the durability of response with various active agents. This translates directly to our Tecmo Key to Development program, which first represents a rational scientific framework to evaluate Treg depletion across a number of cancers and various lines of therapy for response and duration. Secondly, is deliberately constructed to provide insights as to where Treg depletion is best positioned, with what combinations, and in what lines of therapy, and to identify the best patients for long-term survival benefit, the key approval criteria. And importantly, to elucidate the relationship of Treg depletion with immune context, T cells, and other factors necessary for efficacy. Understanding the relationship between biomarkers, immune context factors, and response duration requires a robust biomarker program for context and to provide the direction for future development. We have this in place and are in the process of analyzing this data. Our immune resistance focus on survival and duration clinical benefit also translates to the CasDozo-Ketoc program and the ongoing first-line HCC study in combination with toropalimab and bevacizumab, which follows the previous Cas-O-Zone-Ketox study that demonstrated improved survival and strong complete response data. But noting both the duration and the depth of response took several months. Again, we have the appropriate biomarker program in place and are in the process of analyzing this data now that Catalyze study is fully enrolled. We previewed this for you on our last call. And today, on this call, Dr. Lavallee, our Chief Scientific and Development Officer, will go further and discuss with you TIRI, our Tumor Immune Regulatory Index, in the context of our TAGNO-KETIG studies. Theresa will be followed by our Chief Commercial Officer, Sameer Goregaoker, who will review the Loctorsi business, and Bryan McMichael, our Chief Financial Officer, who will give you some color on our quarterly operational results and cash and balance sheet. But first, let me hand things over to Dr. Dias, our Chief Medical Officer, to provide you an update on the emerging data from the clinical studies. Rosh.